REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gene Security Network Inc. (GSN) today announced that data from studies of GSN’s bioinformatics Parental Support technology will be presented at the American Society for Reproductive Medicine 67th Annual Meeting, Oct. 15-19, at the Orange County Convention Center in Orlando, Fla.
Parental Support is a combination of advanced bioinformatics with single-nucleotide polymorphism (SNP) analysis to generate highly accurate genetic information from small amounts of fetal DNA.
Matthew Rabinowitz, Ph.D., CEO of GSN, will report on the clinical benefit of Parental Support for single gene preimplantation genetic diagnosis (PGD) in parallel with 24-chromosome aneuploidy screening. The presentation will take place during the Preimplantation Genetic Diagnosis oral session at 6 p.m. EDT on Monday, Oct. 17.
Ruth Bunker Lathi, M.D., Director of the Recurrent Pregnancy Loss Program at Stanford University, will present data during the Scientific Program Prize Paper plenary session on use of Parental Support technology for miscarriage products of conception (POC) testing. Miscarriage testing is used to help patients and doctors understand the cause of miscarriage and to inform the patient’s course of therapy. The presentation will take place at 11:30 a.m. EDT on Tuesday, Oct. 18.
In addition to the clinical data featured, Dr. Lathi will present the results of a national survey that evaluated patient interest in products of conception (POC) analysis following miscarriage. The presentation will take place during the Genetic Counseling oral session at 3:45 p.m. EDT on Wednesday, Oct. 19.
About Gene Security Network (GSN)
GSN is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA – as small as that from a single cell. GSN operates a CLIA laboratory in Redwood City, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal diagnosis, currently under clinical trial, to detect chromosomal anomalies by analyzing fragments of fetal DNA in a pregnant mother's blood. For more information, visit www.genesecurity.net.